1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
67542E6814614A3666525852200373334
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-maximizing-impact-medical-affairs-oncology-product-launches-timeline-resources-preparedness?opendocument
18
19opendocument
2034.200.218.187
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Launch Optimization

Maximizing the Impact of Medical Affairs in Oncology Product Launches: Timeline, Resources and Preparedness

ID: 5606


Features:

19 Info Graphics

11 Data Graphics

180+ Metrics


Pages/Slides: 41


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Maximizing the Impact of Medical Affairs in Oncology Product Launches: Timeline, Resources and Preparedness”

STUDY OVERVIEW

As a key conduit between pharma organizations and key opinion leaders, Medical Affairs has become one of the key players in oncology product launches. In order to maximize oncology launch impact, Medical Affairs groups need to develop and maintain a strategic timeline for launch activities; deploy resources at appropriate points in this timeline; and ensure that launch preparedness metrics are used to ensure activities adhere to the timeline.

Best Practices, LLC undertook this benchmarking research to explore how Medical Affairs can maximize its oncology launch impact. This study provides insights and benchmarks around staffing, budgeting, timeline, preparedness metrics, tools and technology for an effective oncology launch. It also highlights the critical success factors and pitfalls for Medical Affairs during oncology launch.

KEY TOPICS

  • Oncology launch timeline
  • Oncology launch resourcing
  • Oncology launch enablers

KEY METRICS
  • Indicate the time when each Medical Affairs group ideally should get involved in oncology product launch activities and when each group actually becomes involved
  • Indicate the total annual Medical Affairs launch investment in U.S. dollars and number of FTEs for your product
  • Indicate the percentage of total Medical Affairs launch budget allocated to each of the listed activities
  • Indicate the percentage of total Medical Affairs staffing allocated to each of the listed activities
  • Have you developed a launch dashboard to measure the value and impact of Medical Affairs role in oncology launch success and to monitor launch progress?
  • In your experience, what have been the critical success factors that drive successful oncology launch for Medical Affairs?
  • What are the major pitfalls for Medical Affairs during oncology product launch?

SAMPLE KEY FINDINGS
  • Develop, deploy and stick to a launch timeline: Use launch roadmap to coordinate the Medical Affairs activities with other functions, understand interdependencies, and which activities to prioritize and where to allocate funding.
    • Develop timeline for critical launch activities around strategy, research, communications, data generation and other activities. Specify discrete and continuous activities.
    • Have a full Medical Affairs team 18-24 months before the launch, including securing the Medical Affairs field resources, leadership and project management milestones.
METHODOLOGY

Best Practices, LLC engaged over 35 oncology Medical Affairs experts from 25 pharmaceutical and biotechnology companies in this research study through a benchmarking survey, interviews and a roundtable discussion.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Chemical; Health Care; Diagnostic; Medical Device


Companies Profiled:
AbbVie; Alkermes; AstraZeneca; Boehringer Ingelheim; Celgene; Cipla; Clovis Oncology; Crescendo Bioscience; Curis; Daiichi Sankyo; Eisai; Exelixis ; GRAIL; Merck; Merck KGaA; Novartis; Roche; Sandoz; Sanofi Genzyme; Servier; Shire; Taiho Oncology; Takeda Pharmaceuticals; Torrent Pharmaceuticals Ltd.; Zydus Cadila

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.